This work is licensed under the Creative Commons Attribution 4.0 International License.
Chapman SJ, Cookson WO, Musk AW, Lee YC. Benign asbestos pleural diseases. Curr Opin Pulm Med 2003; 9: 266–71. doi: 10.1097/00063198-200307000-00004ChapmanSJCooksonWOMuskAWLeeYCBenign asbestos pleural diseasesCurr Opin Pulm Med200392667110.1097/00063198-200307000-00004Open DOISearch in Google Scholar
IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos. IARC Monogr Eval Carcinog Risk Chem Man 1977; 14: 1–106. PMID: 863456IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestosIARC Monogr Eval Carcinog Risk Chem Man1977141106863456Search in Google Scholar
Weiner SJ, Neragi-Miandoab S. Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Cancer Res Clin Oncol 2009; 135: 15–27. doi: 10.1007/s00432-008-0444-9WeinerSJNeragi-MiandoabSPathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factorsJ Cancer Res Clin Oncol2009135152710.1007/s00432-008-0444-9Open DOISearch in Google Scholar
Melaiu O, Gemignani F, Landi S. The genetic susceptibility in the development of malignant pleural mesothelioma. J Thorac Dis 2018; 10: S246–52. doi: 10.21037/jtd.2017.10.41MelaiuOGemignaniFLandiSThe genetic susceptibility in the development of malignant pleural mesotheliomaJ Thorac Dis201810S2465210.21037/jtd.2017.10.41Open DOISearch in Google Scholar
Pylkkänen L, Sainio M, Ollikainen T, Mattson K, Nordling S, Carpén O, et al. Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep 2002; 9: 955–9. doi: 10.3892/or.9.5.955PylkkänenLSainioMOllikainenTMattsonKNordlingSCarpénOConcurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene regionOncol Rep20029955910.3892/or.9.5.955Open DOISearch in Google Scholar
Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999; 180: 150–7. doi: 10.1002/(sici)1097-4652(199908)180:2<150::Aidjcp2>3.0.Co;2-hMurthySSTestaJRAsbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesotheliomaJ Cell Physiol1999180150710.1002/(sici)1097-4652(199908)180:2<150::Aidjcp2>3.0.Co;2-hOpen DOISearch in Google Scholar
Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136–44. doi: 10.2478/v10019-012-0032-0KovacVZwitterMZagarTImproved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patientsRadiol Oncol2012461364410.2478/v10019-012-0032-0Open DOISearch in Google Scholar
Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, et al. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer 2017; 17: 386. doi: 10.1186/s12885-017-3375-5JohnenGGawrychKRaikoICasjensSPeschBWeberDGCalretinin as a blood-based biomarker for mesotheliomaBMC Cancer20171738610.1186/s12885-017-3375-5Open DOISearch in Google Scholar
Carbone M, Adusumilli PS, Alexander HR, Jr., Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 2019; 69: 402–29. doi: 10.3322/caac.21572CarboneMAdusumilliPSAlexanderHRJr.BaasPBardelliFBononiAMesothelioma: scientific clues for prevention, diagnosis, and therapyCA Cancer J Clin2019694022910.3322/caac.21572Open DOISearch in Google Scholar
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018; 142: 89–108. doi: 10.5858/arpa.2017-0124-RAHusainANColbyTVOrdóñezNGAllenTCAttanoosRLBeasleyMBGuidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest GroupArch Pathol Lab Med20181428910810.5858/arpa.2017-0124-RAOpen DOISearch in Google Scholar
Rogers JH. Calretinin: a gene for a novel calcium-binding protein expressed principally in neurons. J Cell Biol 1987; 105: 1343–53. doi: 10.1083/jcb.105.3.1343.RogersJHCalretinin: a gene for a novel calcium-binding protein expressed principally in neuronsJ Cell Biol198710513435310.1083/jcb.105.3.1343Open DOISearch in Google Scholar
Worthmuller J, Blum W, Pecze L, Salicio V, Schwaller B. Calretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathway. Oncotarget 2018; 9: 36256–72. doi: 10.18632/oncotarget.26332WorthmullerJBlumWPeczeLSalicioVSchwallerBCalretinin promotes invasiveness and EMT in malignant mesothelioma cells involving the activation of the FAK signaling pathwayOncotarget20189362567210.18632/oncotarget.26332Open DOISearch in Google Scholar
Parmentier M, Passage E, Vassart G, Mattei MG. The human calbindin D28k (CALB1) and calretinin (CALB2) genes are located at 8q21.3----q22.1 and 16q22----q23, respectively, suggesting a common duplication with the carbonic anhydrase isozyme loci. Cytogenet Cell Genet 1991; 57: 41–3. doi: 10.1159/000133111ParmentierMPassageEVassartGMatteiMGThe human calbindin D28k (CALB1) and calretinin (CALB2) genes are located at 8q21.3----q22.1 and 16q22----q23, respectively, suggesting a common duplication with the carbonic anhydrase isozyme lociCytogenet Cell Genet19915741310.1159/000133111Open DOISearch in Google Scholar
Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R. Serum mesothelin and other biomarkers: what have we learned in the last decade? J Thorac Dis 2018; 10: S353–9. doi: 10.21037/jtd.2017.10.132CristaudoABonottiAGuglielmiGFallahiPFoddisRSerum mesothelin and other biomarkers: what have we learned in the last decade?J Thorac Dis201810S353910.21037/jtd.2017.10.132Open DOISearch in Google Scholar
Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 1541–9. doi: 10.1200/JCO.2011.39.6671HollevoetKReitsmaJBCreaneyJGrigoriuBDRobinsonBWScherpereelASerum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysisJ Clin Oncol2012301541910.1200/JCO.2011.39.6671Open DOISearch in Google Scholar
Raiko I, Sander I, Weber DG, Raulf-Heimsoth M, Gillissen A, Kollmeier J, et al. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients. BMC Cancer 2010; 10: 242. doi: 10.1186/1471-2407-10-242RaikoISanderIWeberDGRaulf-HeimsothMGillissenAKollmeierJDevelopment of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patientsBMC Cancer20101024210.1186/1471-2407-10-242Open DOISearch in Google Scholar
Aguilar-Madrid G, Pesch B, Calderón-Aranda ES, Burek K, Jiménez-Ramírez C, Juárez-Pérez CA, et al. Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population. Int J Med Sci 2018; 15: 883–91. doi: 10.7150/ijms.23939Aguilar-MadridGPeschBCalderón-ArandaESBurekKJiménez-RamírezCJuárez-PérezCABiomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican PopulationInt J Med Sci2018158839110.7150/ijms.23939Open DOISearch in Google Scholar
Jiménez-Ramírez C, Casjens S, Juárez-Pérez CA, Raiko I, Del Razo LM, Taeger D, et al. Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma. Lung 2019; 197: 641–9. doi: 10.1007/s00408-019-00244-1Jiménez-RamírezCCasjensSJuárez-PérezCARaikoIDel RazoLMTaegerDMesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesotheliomaLung2019197641910.1007/s00408-019-00244-1Open DOISearch in Google Scholar
Li D, Wang B, Long H, Wen F. Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis. Sci Rep 2015; 5: 9507. doi: 10.1038/srep09507LiDWangBLongHWenFDiagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysisSci Rep20155950710.1038/srep09507Open DOISearch in Google Scholar
Lehnert M, Weber DG, Taeger D, Raiko I, Kollmeier J, Stephan-Falkenau S, et al. Determinants of plasma calretinin in patients with malignant pleural mesothelioma. BMC Res Notes 2020; 13: 359. doi: 10.1186/s13104-020-05187-yLehnertMWeberDGTaegerDRaikoIKollmeierJStephan-FalkenauSDeterminants of plasma calretinin in patients with malignant pleural mesotheliomaBMC Res Notes20201335910.1186/s13104-020-05187-yOpen DOISearch in Google Scholar
Zupanc C, Franko A, Štrbac D, Dodič Fikfak M, Kovač V, Dolžan V, et al. Serum calretinin as a biomarker in malignant mesothelioma. J Clin Med 2021; 10: 4875. doi: 10.3390/jcm10214875ZupancCFrankoAŠtrbacDDodič FikfakMKovačVDolžanVSerum calretinin as a biomarker in malignant mesotheliomaJ Clin Med202110487510.3390/jcm10214875Open DOISearch in Google Scholar
Casjens S, Weber DG, Johnen G, Raiko I, Taeger D, Meinig C, et al. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study. BMJ Open 2017; 7: e017104. doi: 10.1136/bmjopen-2017-017104CasjensSWeberDGJohnenGRaikoITaegerDMeinigCAssessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort studyBMJ Open20177e01710410.1136/bmjopen-2017-017104Open DOISearch in Google Scholar
Kresoja-Rakic J, Kapaklikaya E, Ziltener G, Dalcher D, Santoro R, Christensen BC, et al. Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells. Oncotarget 2016; 7: 21272–86. doi: 10.18632/oncotarget.7114Kresoja-RakicJKapaklikayaEZiltenerGDalcherDSantoroRChristensenBCIdentification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cellsOncotarget20167212728610.18632/oncotarget.7114Open DOISearch in Google Scholar
Blum W, Pecze L, Rodriguez JW, Steinauer M, Schwaller B. Regulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoter. BMC Cancer 2018; 18: 475. doi: 10.1186/s12885-018-4385-7BlumWPeczeLRodriguezJWSteinauerMSchwallerBRegulation of calretinin in malignant mesothelioma is mediated by septin 7 binding to the CALB2 promoterBMC Cancer20181847510.1186/s12885-018-4385-7Open DOISearch in Google Scholar
Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147–52. doi: 10.1038/nature06487TavazoieSFAlarconCOskarssonTPaduaDWangQBosPDEndogenous human microRNAs that suppress breast cancer metastasisNature20084511475210.1038/nature06487Open DOISearch in Google Scholar
Kresoja-Rakic J, Sulemani M, Kirschner MB, Ronner M, Reid G, Kao S, et al. Posttranscriptional regulation controls calretinin expression in malignant pleural mesothelioma. Front Genet 2017; 8: 70. doi: 10.3389/fgene.2017.00070Kresoja-RakicJSulemaniMKirschnerMBRonnerMReidGKaoSPosttranscriptional regulation controls calretinin expression in malignant pleural mesotheliomaFront Genet201787010.3389/fgene.2017.00070Open DOISearch in Google Scholar
Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V, Franko A. Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases. Radiol Oncol 2020; 54: 86–95. doi: 10.2478/raon-2020-0011GoricarKKovacVDodic-FikfakMDolzanVFrankoAEvaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseasesRadiol Oncol202054869510.2478/raon-2020-0011Open DOISearch in Google Scholar
Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, et al. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. J Thorac Oncol 2014; 9: 1662–8. doi: 10.1097/jto.0000000000000322GarritanoSDe SantiCSilvestriRMelaiuOCipolliniMBaroneEA common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy peopleJ Thorac Oncol201491662810.1097/jto.0000000000000322Open DOISearch in Google Scholar
De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, et al. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. Occup Environ Med 2017; 74: 456–63. doi: 10.1136/oemed-2016-104024De SantiCPucciPBonottiAMelaiuOCipolliniMSilvestriRMesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individualsOccup Environ Med2017744566310.1136/oemed-2016-104024Open DOISearch in Google Scholar
Vonlanthen S, Kawecki TJ, Betticher DC, Pfefferli M, Schwaller B. Heterozygosity of SNP513 in intron 9 of the human calretinin gene (CALB2) is a risk factor for colon cancer. Anticancer Res 2007; 27: 4279–88. PMID: 18214032VonlanthenSKaweckiTJBetticherDCPfefferliMSchwallerBHeterozygosity of SNP513 in intron 9 of the human calretinin gene (CALB2) is a risk factor for colon cancerAnticancer Res20072742798818214032Search in Google Scholar
Tossavainen A. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997; 23: 311–6. doi: 10.5271/sjweh.226TossavainenAAsbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attributionScand J Work Environ Health199723311610.5271/sjweh.226Open DOISearch in Google Scholar
American Thoracic S. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170: 691–715. doi:10.1164/rccm.200310-1436STAmerican ThoracicSDiagnosis and initial management of nonmalignant diseases related to asbestosAm J Respir Crit Care Med200417069171510.1164/rccm.200310-1436STOpen DOISearch in Google Scholar
Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res 2018; 46: D296–302. doi: 10.1093/nar/gkx1067ChouCHShresthaSYangCDChangNWLinYLLiaoKWmiRTarBase update 2018: a resource for experimentally validated microRNA-target interactionsNucleic Acids Res201846D29630210.1093/nar/gkx1067Open DOISearch in Google Scholar
Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37: W600-5. doi: 10.1093/nar/gkp290XuZTaylorJASNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studiesNucleic Acids Res200937W600-510.1093/nar/gkp290Open DOISearch in Google Scholar
Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308–11. doi: 10.1093/nar/29.1.308SherrySTWardMHKholodovMBakerJPhanLSmigielskiEMdbSNP: the NCBI database of genetic variationNucleic Acids Res2001293081110.1093/nar/29.1.308Open DOISearch in Google Scholar
Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PloS One 2012; 7: e50966. doi: 10.1371/journal.pone.0050966SrivastavaKSrivastavaAComprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer riskPloS One20127e5096610.1371/journal.pone.0050966Open DOISearch in Google Scholar
Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012; 40: D930–4. doi: 10.1093/nar/gkr917WardLDKellisMHaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variantsNucleic Acids Res201240D930410.1093/nar/gkr917Open DOISearch in Google Scholar
The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013; 45: 580–5. doi: 10.1038/ng.2653The Genotype-Tissue Expression (GTEx) projectNat Genet201345580510.1038/ng.2653Open DOISearch in Google Scholar
Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 2015; 31: 3555–7. doi: 10.1093/bioinformatics/btv402MachielaMJChanockSJLDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variantsBioinformatics2015313555710.1093/bioinformatics/btv402Open DOISearch in Google Scholar
Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038–9. doi: 10.1093/bioinformatics/btm058TregouetDAGarelleVA new JAVA interface implementation of THESIAS: testing haplotype effects in association studiesBioinformatics2007231038910.1093/bioinformatics/btm058Open DOISearch in Google Scholar
Lehnert M, Weber DG, Taeger D, Raiko I, Kollmeier J, Stephan-Falkenau S, et al. Determinants of plasma calretinin in patients with malignant pleural mesothelioma. BMC Res Notes 2020; 13: 359. doi: 10.1186/s13104-020-05187-yLehnertMWeberDGTaegerDRaikoIKollmeierJStephan-FalkenauSDeterminants of plasma calretinin in patients with malignant pleural mesotheliomaBMC Res Notes20201335910.1186/s13104-020-05187-yOpen DOISearch in Google Scholar
Li L, Wang S, Zhang Y, Pan J. The E2F transcription factor 2: what do we know? Biosci Trends 2021; 15: 83–92. doi: 10.5582/bst.2021.01072LiLWangSZhangYPanJThe E2F transcription factor 2: what do we know?Biosci Trends202115839210.5582/bst.2021.01072Open DOISearch in Google Scholar
Guo AY, Zhai K, Xu JL, Hu JL, Gao L. Identification of a low-frequency mis-sense variant in E2F transcription factor 7 associated with colorectal cancer risk in a chinese population. Asian Pac J Cancer Prev 2017; 18: 271–5. doi: 10.22034/apjcp.2017.18.1.271GuoAYZhaiKXuJLHuJLGaoLIdentification of a low-frequency mis-sense variant in E2F transcription factor 7 associated with colorectal cancer risk in a chinese populationAsian Pac J Cancer Prev201718271510.22034/apjcp.2017.18.1.271Open DOISearch in Google Scholar
Chen J, Etzel CJ, Amos CI, Zhang Q, Viscofsky N, Lindor NM, et al. Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. Cancer Causes Control 2009; 20: 1769–77. doi: 10.1007/s10552-009-9416-xChenJEtzelCJAmosCIZhangQViscofskyNLindorNMGenetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndromeCancer Causes Control20092017697710.1007/s10552-009-9416-xOpen DOISearch in Google Scholar
Gołąbek K, Biernacki K, Gaździcka J, Strzelczyk JK, Miśkiewicz-Orczyk K, Krakowczyk Ł, et al. Selected E2F2 polymorphisms in oral and oropharyngeal squamous cell carcinoma. BioMed Res Int 2021; 2021: 8098130. doi: 10.1155/2021/8098130GołąbekKBiernackiKGaździckaJStrzelczykJKMiśkiewicz-OrczykKKrakowczykŁSelected E2F2 polymorphisms in oral and oropharyngeal squamous cell carcinomaBioMed Res Int20212021809813010.1155/2021/8098130Open DOISearch in Google Scholar
Lu M, Liu Z, Yu H, Wang LE, Li G, Sturgis EM, et al. Combined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neck. Mol Carcinog 2012; 51(Suppl 1): E132–41. doi: 10.1002/mc.21882LuMLiuZYuHWangLELiGSturgisEMCombined effects of E2F1 and E2F2 polymorphisms on risk and early onset of squamous cell carcinoma of the head and neckMol Carcinog201251Suppl 1E1324110.1002/mc.21882Open DOISearch in Google Scholar
Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, et al. Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer 2009; 101: 1461–8. doi: 10.1038/sj.bjc.6605284CunninghamJMVierkantRASellersTAPhelanCRiderDNLiebowMCell cycle genes and ovarian cancer susceptibility: a tagSNP analysisBr J Cancer20091011461810.1038/sj.bjc.6605284Open DOISearch in Google Scholar
Li Y, Sturgis EM, Zhu L, Cao X, Wei Q, Zhang H, et al. E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog 2017; 56: 1335–43. doi: 10.1002/mc.22595LiYSturgisEMZhuLCaoXWeiQZhangHE2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynxMol Carcinog20175613354310.1002/mc.22595Open DOISearch in Google Scholar
Scarpulla RC. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann N Y Acad Sci 2008; 1147: 321–34. doi: 10.1196/annals.1427.006ScarpullaRCNuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivatorAnn N Y Acad Sci200811473213410.1196/annals.1427.006Open DOISearch in Google Scholar
Bhawe K, Roy D. Interplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progression. Cell Oncol (Dordr) 2018; 41: 465–84. doi: 10.1007/s13402-018-0395-3BhaweKRoyDInterplay between NRF1, E2F4 and MYC transcription factors regulating common target genes contributes to cancer development and progressionCell Oncol (Dordr)2018414658410.1007/s13402-018-0395-3Open DOISearch in Google Scholar
Crocco P, Montesanto A, Passarino G, Rose G. Polymorphisms falling within putative miRNA target sites in the 3′UTR region of SIRT2 and DRD2 genes are correlated with human longevity. J Gerontol A Biol Sci Med Sci 2016; 71: 586–92. doi: 10.1093/gerona/glv058CroccoPMontesantoAPassarinoGRoseGPolymorphisms falling within putative miRNA target sites in the 3′UTR region of SIRT2 and DRD2 genes are correlated with human longevityJ Gerontol A Biol Sci Med Sci2016715869210.1093/gerona/glv058Open DOISearch in Google Scholar
Qu L, He B, Pan Y, Xu Y, Zhu C, Tang Z, et al. Association between polymorphisms in RAPGEF1, TP53, NRF1 and type 2 diabetes in Chinese Han population. Diabetes Res Clin Pract 2011; 91: 171–6. doi: 10.1016/j.diabres.2010.11.019QuLHeBPanYXuYZhuCTangZAssociation between polymorphisms in RAPGEF1, TP53, NRF1 and type 2 diabetes in Chinese Han populationDiabetes Res Clin Pract201191171610.1016/j.diabres.2010.11.019Open DOISearch in Google Scholar
Liu Y, Niu N, Zhu X, Du T, Wang X, Chen D, et al. Genetic variation and association analyses of the nuclear respiratory factor 1 (nRF1) gene in Chinese patients with type 2 diabetes. Diabetes 2008; 57: 777. doi: 10.2337/db07-0008LiuYNiuNZhuXDuTWangXChenDGenetic variation and association analyses of the nuclear respiratory factor 1 (nRF1) gene in Chinese patients with type 2 diabetesDiabetes20085777710.2337/db07-0008Open DOISearch in Google Scholar
Permuth-Wey J, Chen YA, Tsai YY, Chen Z, Qu X, Lancaster JM, et al. Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20: 1131–45. doi: 10.1158/1055-9965.Epi-10-1224Permuth-WeyJChenYATsaiYYChenZQuXLancasterJMInherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer riskCancer Epidemiol Biomarkers Prev20112011314510.1158/1055-9965.Epi-10-1224Open DOISearch in Google Scholar
Shen S, Wei Y, Li Y, Duan W, Dong X, Lin L, et al. A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival. NPJ Precis Oncol 2021; 5: 39. doi: 10.1038/s41698-021-00182-3ShenSWeiYLiYDuanWDongXLinLA multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survivalNPJ Precis Oncol202153910.1038/s41698-021-00182-3Open DOISearch in Google Scholar
Wang X, Fei F, Qu J, Li C, Li Y, Zhang S. The role of septin 7 in physiology and pathological disease: a systematic review of current status. J Cell Mol Med 2018; 22: 3298–307. doi: 10.1111/jcmm.13623WangXFeiFQuJLiCLiYZhangSThe role of septin 7 in physiology and pathological disease: a systematic review of current statusJ Cell Mol Med201822329830710.1111/jcmm.13623Open DOISearch in Google Scholar
Zhu C, Hu H, Li J, Wang J, Wang K, Sun J. Identification of key differentially expressed genes and gene mutations in breast ductal carcinoma in situ using RNA-seq analysis. World J Surg Oncol 2020; 18: 52. doi: 10.1186/s12957-020-01820-zZhuCHuHLiJWangJWangKSunJIdentification of key differentially expressed genes and gene mutations in breast ductal carcinoma in situ using RNA-seq analysisWorld J Surg Oncol2020185210.1186/s12957-020-01820-zOpen DOISearch in Google Scholar
Ye L, Wang F, Wu H, Yang H, Yang Y, Ma Y, et al. Functions and targets of miR-335 in cancer. Onco Targets Ther 2021; 14: 3335–49. doi: 10.2147/ott.S305098YeLWangFWuHYangHYangYMaYFunctions and targets of miR-335 in cancerOnco Targets Ther20211433354910.2147/ott.S305098Open DOISearch in Google Scholar
Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, et al. Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat 2011; 127: 549–54. doi: 10.1007/s10549-010-1244-xYangRDickMMarmeFSchneeweissALangheinzAHemminkiKGenetic variants within miR-126 and miR-335 are not associated with breast cancer riskBreast Cancer Res Treat20111275495410.1007/s10549-010-1244-xOpen DOISearch in Google Scholar